KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Short-term Investments (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Short-term Investments for 6 consecutive years, with $4.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments rose 50.87% year-over-year to $4.6 million, compared with a TTM value of $4.6 million through Dec 2025, up 50.87%, and an annual FY2025 reading of $4.6 million, up 50.87% over the prior year.
  • Short-term Investments was $4.6 million for Q4 2025 at Recursion Pharmaceuticals, up from $3.1 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $231.4 million in Q4 2021 and bottomed at $1.3 million in Q4 2022.
  • Average Short-term Investments over 5 years is $14.9 million, with a median of $3.1 million recorded in 2025.
  • The sharpest move saw Short-term Investments soared 4491.27% in 2021, then plummeted 99.45% in 2022.
  • Year by year, Short-term Investments stood at $231.4 million in 2021, then tumbled by 99.45% to $1.3 million in 2022, then soared by 152.42% to $3.2 million in 2023, then decreased by 5.76% to $3.0 million in 2024, then skyrocketed by 50.87% to $4.6 million in 2025.
  • Business Quant data shows Short-term Investments for RXRX at $4.6 million in Q4 2025, $3.1 million in Q3 2025, and $3.1 million in Q2 2025.